Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TSB-IL17A
- Development stage
- Preclinical
- Lead developer
- TargetSite Therapeutics
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Oral, Intranasal, Rectal, Intravaginal, Parenteral, Buccal, Sublingual, Topical, Intramuscular, Intravenous, Arterial, Subcutaneous, Inhalation, Ophthalmic, Pulmonary
01
Overview
TSB-IL17A is a preclinical-stage oligonucleotide therapeutic developed by TargetSite Therapeutics, a Yale University spinout. It utilizes the company's proprietary TargetSite Blocker (TSB) platform to modulate IL-17A expression. Unlike traditional antisense oligonucleotides that trigger RNase H-mediated cleavage, TSB-IL17A specifically blocks the binding of microRNA miR466l-3p to the 3' untranslated region (UTR) of IL-17A mRNA. In this specific biological context, miR466l-3p acts as an enhancer of IL-17A expression by cooperating with the RNA-stabilizing protein HuR; by disrupting this interaction, TSB-IL17A promotes mRNA decay and reduces IL-17A protein production. The drug is being investigated for the treatment of chronic inflammatory and autoimmune conditions, including autoimmune uveitis, psoriasis, and multiple sclerosis (modeled by experimental autoimmune encephalomyelitis).
- Other names
- TSB (TargetSite Blocker) - IL-17A inhibitorTSB IL-17A
02
Targets
IL-17A (Interleukin-17A)
Beyond the preview
Go deeper on TSB-IL17A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TSB-IL17A.